Table of Contents
Executive Summary
- 2007-2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician Perspectives: Findings of Our Primary Research
Section 1: Introduction
- Scope of the Report
- Survey Methodology
Section 2: Atypical Antipsychotics Market Dynamics
- Atypical Antipsychotics Background
- Prescribers
- Prescriber Trends
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Generalized Anxiety Disorder
- Key Drivers of Prescriber Decisions
- Treatment Dynamics
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Anxiety Disorders
- Usage Patterns for Atypical Antipsychotics
- Key Competing Classes
- Antiepileptics
- Antidepressants
- Lithium
- Benzodiazepines
- Reimbursement Issues
- United States
- Europe
- Japan
- Perceptions of Atypical Antipsychotic Reimbursement
Section 3: Competitive Analysis
- Overview of Competitive Landscape
- Promotional Spending
- Brand-Specific Trends
- Physician Perceptions of Atypical Antipsychotic Brand Promotion
- Comparative Labeling for Key Brands
- Indication Approvals
- Warnings and Side Effects
- Comparative Pricing of Key Brands
- Physician Perceptions
- Perceptions of Competitors in Atypical Antipsychotics
- Perceptions of Brands in Atypical Antipsychotics
- Perceptions of Atypical Antipsychotic Brands by Indication
- Perceptions of Atypical Antipsychotic Brands on Side Effects
- Perceptions of Atypical Antipsychotic Brands on Delivery Attributes
- Perceptions of Atypical Antipsychotic Brands on Clinical Trial Data
- Perceptions of Messaging in Atypical Antipsychotics
Section 4: Established Competitors
- Eli Lilly
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Zyprexa
- Current Positioning
- Zyprexa Competitive Analysis
- Key Brand Strategies
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Janssen (Johnson & Johnson)
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Pricing Strategy
- Risperdal
- Current Positioning
- Risperdal Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Messaging
- Future Positioning and Outlook
- Invega
- Current Positioning
- Invega Competitive Analysis
- Key Brand Strategies
- Current Strategy in the Atypical Antipsychotics Market
- Messaging
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- AstraZeneca
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Seroquel
- Current Positioning
- Seroquel Competitive Analysis
- Key Brand Strategies
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Bristol-Myers Squibb
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Abilify
- Current Positioning
- Abilify Competitive Analysis
- Key Brand Strategies
- Licensing Strategy
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Otsuka Company
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Abilify
- Pfizer
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Geodon
- Current Positioning
- Geodon Competitive Analysis
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
Section 5: Emerging Competitors
- Physician Perceptions
- Perceptions of Emerging Atypical Antipsychotics
- Schering-Plough/Organon
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Asenapine
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Wyeth
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Bifeprunox
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Solvay Pharmaceuticals
- Strategic Overview
- Neuroscience Product Portfolio
- Bifeprunox
- Vanda
- Strategic Overview
- Neuroscience Product Portfolio
- Iloperidone
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- H. Lundbeck
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Serdolect
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Dainippon Sumitomo
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Lonasen
- Development and Commercial Overview
- Future Positioning and Outlook
- Forest Laboratories
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- RGH-188
- Development and Commercial Overview
- Future Positioning and Outlook
Section 6: Market Forecast
- Atypical Antipsychotics Market Analysis
- Sales Trends by Region
- Sales Trends by Indication
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Generalized Anxiety Disorder
- Sales Trends by Brand
- Key Patient Populations-Schizophrenia, Bipolar Disorder, Major Depression,
Generalized Anxiety Disorder
- Prevalent Populations of Key Diseases
- Diagnosed Populations of Key Diseases
- Drug-Treated Populations of Key Diseases
Section 7: Appendices
- Acronyms and Abbreviations
- Bibliography
- Methodology
- Epidemiology
- Market Forecast
- Competitive Analysis
- Authors
- About the Authors
- About Decision Resources, Inc.
- For More Information:
Table of Exhibits
Executive Summary
- Exhibit 1: Key Parameters of the Atypical Antipsychotics Market
- Exhibit 2: Atypical Antipsychotics Branded Market, ($MM), Major Markets,
2007-2012
- Exhibit 3: Atypical Antipsychotics Market Competitive Position, 2007 and
2012
- Exhibit 4: Antipsychotics Market, by Company, as a % of Total, 2007 and
2012
- Exhibit 5: Atypical Antipsychotic Brands Market Share, 2007 and 2012
- Exhibit 6: Physician Familiarity with Key Emerging Agents
- Exhibit 7: Surveyed Physicians' Years of Practice
- Exhibit 8: Surveyed Physicians' Patients per Month
- Exhibit 9: Surveyed Physicians' Geographic Distribution
- Exhibit 10: Currently Marketed Atypical Antipsychotic Brands
- Exhibit 11: DSM-IV Diagnostic Criteria for Schizophrenia
- Exhibit 12: Most Influential Factors for Choosing a Specific Atypical
Antipsychotic
- Exhibit 13: Physicians' Preferred Information Sources for Atypical
Antipsychotics
- Exhibit 14: Frequency of Use of Information Sources for Atypical
Antipsychotics
- Exhibit 15: Treatment Algorithm for Schizophrenia
- Exhibit 16: Treatment Algorithm for Bipolar Mania
- Exhibit 17: Treatment Algorithm for Bipolar Depression
- Exhibit 18: Treatment Algorithm for Major Depression
- Exhibit 19: Treatment Algorithm for Anxiety Disorders
- Exhibit 20: Percentage of Branded Antipsychotics' Prescriptions by Brand,
by Indication, and by Region, 2006
- Exhibit 21: Class-Level Patient Share Within Selected Indications, U.S.,
2007
- Exhibit 22: U.S. Formulary Status of Leading Atypical Antipsychotics
- Exhibit 23: Medicaid Formulary Status of Leading Atypical Antipsychotics
- Exhibit 24: Medicare Formulary Status of Leading Atypical Antipsychotics
- Exhibit 25: Physician Perceptions of Zyprexa' s Reimbursement
- Exhibit 26: Physician Perceptions of Risperdal' s Reimbursement
- Exhibit 27: Physician Perceptions of Invega' s Reimbursement
- Exhibit 28: Physician Perceptions of Seroquel' s Reimbursement
- Exhibit 29: Physician Perceptions of Abilify' s Reimbursement
- Exhibit 30: Physician Perceptions of Geodon' s Reimbursement
- Exhibit 31: Atypical Antipsychotics Sales ($MM), by Country, 2007
- Exhibit 32: Atypical Antipsychotics Market Competitive Position, 2007 and
2012
- Exhibit 33: Atypical Antipsychotics Major-Market Sales ($MM), by Brand,
2007-2012
- Exhibit 34: Promotional Spend for Atypical Antipsychotics Therapies, by
Company, 2006
- Exhibit 35: Promotional Spend, by Competitor, as a % of Total Promotional
Spend for Atypical Antipsychotics, 2004-2006
- Exhibit 36: Promotional Spend for Atypical Antipsychotics, by Brand, 2006
- Exhibit 37: Physician Perception of the Atypical Antipsychotic with the
Most Promotional Material
- Exhibit 38: Physician Perception of the Atypical Antipsychotic with the
Most Patient Requests
- Exhibit 39: Physician Perception of the Most Important Channel
Schizophrenic Patients Use to Learn About Atypical Antipsychotics
- Exhibit 40: Physician Perception of the Most Important Channel Bipolar
Patients Use to Learn About Atypical Antipsychotics
- Exhibit 41: Physician Perception of the Most Important Channel Major
Depression Patients Use to Learn About Atypical Antipsychotics
- Exhibit 42: Physician Perception of the Most Important Channel Generalized
Anxiety Disorder Patients Use to Learn About Atypical Antipsychotics
- Exhibit 43: Labeled Indications for Key Brands, 2007
- Exhibit 44: Labeled Warnings Comparison for Key Brands, 2007
- Exhibit 45: Price per Day ($), Key Brands, Schizophrenia, 2006
- Exhibit 46: Price per Day ($), Key Brands, Bipolar Disorder, 2006
- Exhibit 47: Price per Day ($), Key Brands, Major Depression, 2006
- Exhibit 48: Price per Day ($), Key Brands, Generalized Anxiety Disorder,
2006
- Exhibit 49: Physician Top-of-Mind Mentions for Atypical Antipsychotics
Pharmaceutical Companies
- Exhibit 50: Physician Perception of the Reputations of Atypical
Antipsychotics Competitors
- Exhibit 51: Factors Impacting Physician Perception of Competitors in the
Atypical Antipsychotics Market
- Exhibit 52: Physician Rankings of "Best" Companies in the Atypical
Antipsychotics Market
- Exhibit 53: Physician Rankings of Competitors, by Attributes
- Exhibit 54: Physician Familiarity with Atypical Antipsychotic Brands
- Exhibit 55: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Schizophrenia
- Exhibit 56: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Bipolar Disorder
- Exhibit 57: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Major Depression
- Exhibit 58: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Generalized Anxiety Disorder
- Exhibit 59: Physician Perceptions of Whether Weight Gain/Metabolic Side
Effects Are an Advantage, by Brand
- Exhibit 60: Physician Perceptions of Whether EPS or Other Movement Side
Effects Are an Advantage, by Brand
- Exhibit 61: Physician Perceptions of Whether Cardiovascular Side Effects
Are an Advantage, by Brand
- Exhibit 62: Physician Perceptions of Whether Compliance Is an Advantage,
by Brand
- Exhibit 63: Physician Perceptions of Whether Cost Is an Advantage, by Brand
- Exhibit 64: Physician Perceptions of Whether the Weight of Evidence from
Clinical Trials Is an Advantage, by Brand
- Exhibit 65: Physician Perceptions of Whether the Amount of Available Drug
Data in Other Indications Is an Advantage, by Brand
- Exhibit 66: Physician Perceptions of the Atypical Antipsychotic That
Benefited the Most Based on Publication of Results from CATIE Trials
- Exhibit 67: Physician Response to Marketing Messages for a Hypothetical
Atypical Antipsychotic Brand
- Exhibit 68: Physician Perception of Core Marketing Messages for Atypical
Antipsychotics
- Exhibit 69: Physician Perception of Most Influential Branded-Drug
Messaging in the Atypical Antipsychotics Market
- Exhibit 70: Physician Identification of Slogans to the Correct Atypical
Antipsychotic Brands
- Exhibit 71: Summary of Eli Lilly' s Neuroscience Product Portfolio
- Exhibit 72: Physician Perceptions of Zyprexa' s Efficacy
- Exhibit 73: Physician Perceptions of Zyprexa' s Drug Attributes
- Exhibit 74: Drug Prescriptions to Be Replaced by Zyprexa Adhera if It
Becomes Commercially Available
- Exhibit 75: Ongoing Eli Lilly-Sponsored Phase III and IV Clinical Trials
for Zyprexa
- Exhibit 76: Ongoing Phase III and IV Clinical Trials for Zyprexa Adhera
- Exhibit 77: Zyprexa Sales by Formulation ($MM), 2007-2012
- Exhibit 78: Zyprexa Sales by Region ($MM), 2007-2012
- Exhibit 79: Zyprexa Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 80: Summary of Johnson & Johnson' s Central Nervous System Product
Portfolio
- Exhibit 81: Physician Perceptions of Risperdal' s Efficacy
- Exhibit 82: Physician Perceptions of Risperdal' s Drug Attributes
- Exhibit 83: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Risperdal
- Exhibit 84: Ongoing Phase III and IV Clinical Trials for Risperdal Consta
- Exhibit 85: Risperdal Sales by Formulation ($MM), 2007-2012
- Exhibit 86: Risperdal Sales by Region ($MM), 2007-2012
- Exhibit 87: Risperdal Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 88: Physician Perceptions of Invega' s Efficacy
- Exhibit 89: Physician Perceptions of Invega' s Drug Attributes
- Exhibit 90: Drug Prescriptions to Be Replaced by Paliperidone Palmitate
(Depot) if It Becomes Commercially Available
- Exhibit 91: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Invega
- Exhibit 92: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Paliperidone Palmitate
- Exhibit 93: Invega Sales by Formulation ($MM), 2007-2012
- Exhibit 94: Invega Sales by Region ($MM), 2007-2012
- Exhibit 95: Invega Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 96: Summary of AstraZeneca' s Neuroscience Product Portfolio
- Exhibit 97: Physician Perceptions of Seroquel' s Efficacy
- Exhibit 98: Physician Perceptions of Seroquel' s Drug Attributes
- Exhibit 99: Drug Prescriptions to be Replaced by Seroquel XR
- Exhibit 100: Ongoing AstraZeneca-Sponsored Phase III and IV Clinical
Trials for Seroquel
- Exhibit 101: Ongoing AstraZeneca-Sponsored Phase III and IV Clinical
Trials for Seroquel XR
- Exhibit 102: Seroquel Sales, by Region ($MM), 2007-2012
- Exhibit 103: Seroquel Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 104: Summary of Bristol-Myers Squibb' s Neuroscience Product
Portfolio
- Exhibit 105: Physician Perceptions of Abilify' s Efficacy
- Exhibit 106: Physician Perceptions of Abilify' s Drug Attributes
- Exhibit 107: Ongoing Bristol-Myers Squibb-Sponsored Phase III and IV
Clinical Trials for Abilify
- Exhibit 108: Ongoing Otsuka-Sponsored Phase III and IV Clinical Trials for
Abilify
- Exhibit 109: Ongoing Bristol-Myers Squibb Academic-Sponsored Phase III and
IV Clinical Trials for Abilify
- Exhibit 110: Abilify Sales by Formulation ($MM), 2007-2012
- Exhibit 111: Abilify Sales by Region ($MM), 2007-2012
- Exhibit 112: Abilify Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 113: Summary of Otsuka' s Neuroscience Product Portfolio
- Exhibit 114: Summary of Pfizer' s Neuroscience Product Portfolio
- Exhibit 115: Physician Perceptions of Geodon' s Efficacy
- Exhibit 116: Physician Perceptions of Geodon' s Drug Attributes
- Exhibit 117: Ongoing Pfizer- Sponsored Phase III and IV Clinical Trials
for Geodon
- Exhibit 118: Ongoing Pfizer Academic-Sponsored Phase III and IV Clinical
Trials for Geodon
- Exhibit 119: Geodon Sales by Formulation ($MM), 2007-2012
- Exhibit 120: Geodon Sales by Region ($MM), 2007-2012
- Exhibit 121: Geodon Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 122: Physician Familiarity with Antipsychotics in Late-Stage
Development
- Exhibit 123: Physician Ranking of Emerging Antipsychotics
- Exhibit 124: Factors Prior to Launch Affecting Physicians' Willingness to
Prescribe Emerging Antipsychotics
- Exhibit 125: Summary of Organon' s Neuroscience Product Portfolio
- Exhibit 126: Summary of Schering-Plough' s Neuroscience Product Portfolio
- Exhibit 127: Drug Prescriptions to Be Replaced by Asenapine if It Becomes
Commercially Available
- Exhibit 128: Asenapine Sales by Region ($MM), 2007-2012
- Exhibit 129: Expected Asenapine Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 130: Summary of Wyeth' s Neuroscience Product Portfolio
- Exhibit 131: Drug Prescriptions to Be Replaced by Bifeprunox if It Becomes
Commercially Available
- Exhibit 132: Bifeprunox Sales by Region ($MM), 2007-2012
- Exhibit 133: Expected Bifeprunox Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 134: Summary of Solvay' s Neuroscience Product Portfolio
- Exhibit 135: Drug Prescriptions to Be Replaced by Iloperidone if It
Becomes Commercially Available
- Exhibit 136: Iloperidone Sales ($MM), 2007-2012
- Exhibit 137: Expected Iloperidone Sales ($MM) and Market Share, by
Country, 2007-2012
- Exhibit 138: Serdolect Sales ($MM), 2007-2012
- Exhibit 139: Expected Serdolect Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 140: Summary of Dainippon Sumitomo' s Neuroscience Product Portfolio
- Exhibit 141: Lonasen Sales ($MM), 2007-2012
- Exhibit 142: Expected Lonasen Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 143: Physician Willingness to Prescribe a Generic Antipsychotic in
the First Year of Its Availability
- Exhibit 144: Atypical Antipsychotics Market ($MM), Major Markets, 2007-2012
- Exhibit 145: Atypical Antipsychotics Market ($MM), Major Markets,
2007-2012 by Region
- Exhibit 146: Timeline of Key Events, Atypical Antipsychotics Market,
2007-2012
- Exhibit 147: Key Launch Events, Atypical Antipsychotics Market, 2007-2012
- Exhibit 148: Expected Generic Entries, Atypical Antipsychotics Market,
2007-2012
- Exhibit 149: Physician Perception of the Impact of Future Events in the
Atypical Antipsychotics Market
- Exhibit 150: Atypical Antipsychotics Market ($MM), by Country (Graphical
Format), 2007-2012
- Exhibit 151: Atypical Antipsychotics Market ($MM), by Country (Tabular
Format), 2007-2012
- Exhibit 152: Key Atypical Antipsychotic Brands, by Indication, as a % of
Total, 2007 and 2012
- Exhibit 153: Zyprexa Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 154: Risperdal Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 155: Seroquel Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 156: Abilify Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 157: Geodon Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 158: Atypical Antipsychotics Market ($MM), by Brand (Graphical
Format), 2007-2012
- Exhibit 159: Atypical Antipsychotics Market ($MM), by Brand (Tabular
Format), 2007-2012
- Exhibit 160: Prevalent Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 161: Diagnosed Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 162: Drug-Treated Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 163: Drug-Treated Populations for Key Diseases in the Atypical
Antipsychotics Market, by Region, 2007 and 2012
- Exhibit 164: Drug-Treated Populations for Key Diseases in the Atypical
Antipsychotics Market, by Region, 2007-2012
|
Related Report
|
View Cart
